(Scale All Share, Construction & Materials, H5E GR)



Buy EUR 77.50		Value Indicators: DCF:		ESG Score (MSCI based): 3.0 Balance Sheet Score: 2.8		Description: Service provider for construction of owner-occupied homes and holiday property		
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2022e	
		Market cap:	159.2	Freefloat	69.90 %	Beta:	1.6	
Price	EUR 39.80	No. of shares (m):	4.0	Karl-Heinz Maerzke	29.80 %	Price / Book:	1.1 x	
Upside	94.7 %	EV:	385.5	Management board	0.30 %	Equity Ratio:	30 %	
o possio	· · · · · · · · · · · · · · · · · · ·	Freefloat MC:	111.3			Net Fin. Debt / EBITDA:	6.7 x	
		Ø Trad. Vol. (30d):	144.22 th			Net Debt / EBITDA:	6.7 x	


Robust development in a challenging environment

Meeting Highlights

- Despite the challenging environment, demand for HELMA's properties has been satisfactory and the cancellation risk is not material. HELMA should rather have benefitted from the continuation of good demand for individual and pre-planned units in attractive locations, as fear of inflation supported overall demand. This should partly compensate for the lower demand anticipated for detached houses at HELMA Eigenheimbau, as this segment should be negatively influenced by rising financing costs, with interest rates for mortgage loans most recently increasing from 1% to 3.5% in just four months. Demand at HELMA Ferienimmobilien should normalise in H1 compared to last year (H1/21: EUR 43.2m) but is expected to be strong compared to order intake in the years before, e.g. in H1/2020 (EUR 23.9m). The project pipeline is strong with the sales start of attractive units planned in 2023.
- HELMA's customer focus had already changed in recent years owing to a stronger focus on high-quality building materials and house configuration. The customer focus has shifted to more wealthy clients who are able to shoulder a higher financial burden from rising interest rates. Nevertheless, the interest rate hike will be an obstacle for some potential customers to buy in the near future.
- As a larger developer, HELMA generally has better access to the required building materials (positive for subcontractors), which is very helpful in completing the construction in the expected timeframe. Furthermore, HELMA has continuously increased the selling prices for its houses in all segments due to higher building material prices. In 2022, the price increases averaged ~11% and should help to achieve at least a stable margin development.
- HELMA's 2022 guidance of a sales volume of EUR 360-380m and EBT of EUR 30-33m seems conservative as it includes several cautious assumptions regarding the development of building material prices, material shortages and the postponement of projects as a consequence. Furthermore, under normal circumstances, the order book of EUR 360m at the end of 2021 would enable a turnover of 20-30% above this level in the following year. Therefore, only modest normalisation would have allowed for a guidance beat (comparable to the March 2021 guidance increase for 2021). Unfortunately, headwinds have strengthened with the negative impact of the Ukraine war (e.g. energy prices) and interest rate hikes and, for this reason, the guidance seems realistic and within reach considering the current developments.

Conclusion

- Order intake should be very robust based on the good product pipeline and the improving financial strength of HELMA's customer base. We assume only a modest decline in H1 and ~12% for the FY 2022 on an adjusted basis (w/o estimated one-off effect due to end of subsidies).
- HELMA is still benefitting from the demand for properties in attractive locations in its portfolio. Although we expect lower demand, reflecting a normalisation, it is also worth noting that the supply of properties offered in the market should also decrease, allowing for attractive margins.
- The valuation looks undernanding with a book value of EUR 31.50/share and estimated hidden reserves of EUR 120-150m from acquired sites, which would already lead to a combined value of EUR 65.2 per share. Our price target of EUR 77.50 offers upside of more than 90%.



Rel. Performance vs Scale A	11
1 month:	-4.2 %
6 months:	-16.1 %
Year to date:	-16.6 %
Trailing 12 months:	-10.5 %
Company events:	

FY End: 31.12. in EUR m	CAGR (21-24e)	2018	2019	2020	2021	2022e	2023e	2024e
Sales	7.3 %	253.3	263.2	274.0	331.5	364.6	371.9	409.1
Change Sales yoy		-5.0 %	3.9 %	4.1 %	21.0 %	10.0 %	2.0 %	10.0 %
Gross margin adj.	-1.3 %	23.8 %	24.5 %	24.1 %	24.7 %	23.2 %	23.9 %	23.7 %
EBITDA	12.6 %	23.8	25.2	24.8	30.6	33.6	37.1	43.8
EBIT	13.7 %	21.8	22.8	22.2	27.9	30.8	34.3	41.0
Margin		8.6 %	8.7 %	8.1 %	8.4 %	8.4 %	9.2 %	10.0 %
EBT		21.2	23.6	22.5	27.3	29.9	33.3	40.0
Net income	13.4 %	14.5	16.1	15.4	18.8	20.4	22.8	27.4
EPS	13.4 %	3.62	4.04	3.84	4.69	5.11	5.69	6.84
EPS adj.	13.4 %	3.62	4.04	3.84	4.69	5.11	5.69	6.84
DPS	6.9 %	1.30	1.85	1.54	1.72	1.95	2.10	2.10
Dividend Yield		3.5 %	4.9 %	4.2 %	2.9 %	4.9 %	5.3 %	5.3 %
FCFPS		-0.25	-1.44	-2.99	-0.46	-1.02	-0.52	-1.02
FCF / Market cap		-0.7 %	-3.8 %	-8.1 %	-0.8 %	-2.6 %	-1.3 %	-2.6 %
EV / Sales		1.2 x	1.2 x	1.3 x	1.3 x	1.1 x	1.1 x	1.0 x
EV / EBITDA		12.9 x	13.0 x	14.0 x	14.5 x	11.5 x	10.8 x	9.5 x
EV / EBIT		14.1 x	14.4 x	15.6 x	16.0 x	12.5 x	11.7 x	10.2 x
P/E		10.2 x	9.4 x	9.6 x	12.5 x	7.8 x	7.0 x	5.8 x
P / E adj.		10.2 x	9.4 x	9.6 x	12.5 x	7.8 x	7.0 x	5.8 x
FCF Potential Yield		5.1 %	5.0 %	4.7 %	4.7 %	5.9 %	6.3 %	7.1 %
Net Debt		159.3	175.7	199.1	211.7	226.3	241.2	258.1
ROCE (NOPAT)		6.0 %	5.8 %	5.1 %	5.9 %	5.9 %	6.1 %	6.7 %
Guidance:	2022: Sales El	UR 360-380r	n, EBT EUR	30-33m; 202	4: Sales EUF	R >>400m. E	BT EUR >>4	0m


01.07.22

11.08.22

AGM

H1





Company Background

- Provider of construction services for brick-built homes that can be adapted to individual tastes.
- Focus on product development, sale, planning and building administration. Construction is outsourced to subcontractors.
- Via HELMA Wohnungsbau GmbH, HELMA in its role as a developer, acquires larger areas zoned for residential construction with up to 250 building sites. Regional focus is on cities like Berlin, Hamburg, Hanover or Munich.
- Since early 2011 the company has been developing and selling holiday properties at the North Sea and Baltic Sea coasts, at attractive lakeside locations and the low mountain range via the subsidiary HELMA Ferienimmobil.

Competitive Quality

- Individualisation without additional costs: HELMA's homes are mainly distinguished by the range of individual design options at no extra cost.
- High expertise in the future market of energy-efficient houses: HELMA offers a broad range of energy-efficient houses with the efficiency house 55 EE as a minimum standard.
- Efficient sales concept: HELMA's 35 show houses throughout Germany are used by ca. 80 freelance sales representatives as a point of sale.
- Business model expansion into apartment building completes product range
- Successful advancement of the development business in the holiday property area since 2011. Gradual expansion of the market positioning makes attractive growth possible.





DCF model														
	Detaile	d forecas	t period				7	ransition	al period					Term. Value
Figures in EUR m	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	
Sales	364.6	371.9	409.1	441.8	475.0	503.5	533.7	560.4	588.4	606.1	618.2	630.5	n.a.	
Sales change	10.0 %	2.0 %	10.0 %	8.0 %	7.5 %	6.0 %	6.0 %	5.0 %	5.0 %	3.0 %	2.0 %	2.0 %	n.a.	1.5 %
EBIT	30.8	34.3	41.0	46.4	49.9	52.9	56.0	56.0	58.8	57.6	58.7	56.7	n.a.	
EBIT-margin	8.4 %	9.2 %	10.0 %	10.5 %	10.5 %	10.5 %	10.5 %	10.0 %	10.0 %	9.5 %	9.5 %	9.0 %	n.a.	
Tax rate (EBT)	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	31.5 %	n.a.	
NOPAT	21.1	23.5	28.1	31.8	34.2	36.2	38.4	38.4	40.3	39.4	40.2	38.9	n.a.	
Depreciation	2.8	2.8	2.8	3.5	3.8	4.0	4.3	4.5	4.7	4.8	4.9	5.0	n.a.	
in % of Sales	0.8 %	0.8 %	0.7 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	0.8 %	n.a.	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a.	
Change in Liquidity from														
- Working Capital	28.9	29.6	35.6	37.4	33.7	28.4	22.0	17.1	17.4	5.9	-0.2	-0.5	n.a.	
- Capex	3.2	3.4	3.4	4.0	4.3	4.5	4.8	5.0	5.3	5.5	5.6	5.7	n.a.	
Capex in % of Sales	0.9 %	0.9 %	0.8 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	0.9 %	n.a.	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	n.a.	
Free Cash Flow (WACC Model)	-8.3	-6.7	-8.1	-6.0	-0.1	7.3	15.9	20.7	22.3	32.9	39.9	38.7	n.a.	30
PV of FCF	-8.5	-6.5	-7.5	-5.3	0.0	5.7	11.9	14.7	15.0	20.9	24.0	22.1	n.a.	414
share of PVs		-4.29 %						25.23	3 %					79.07 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2034e	110		
				Terminal Value	414		
Debt ratio	41.00 %	Financial Strength	1.50	Financial liabilities	234		
Cost of debt (after tax)	2.6 %	Liquidity (share)	2.00	Pension liabilities	0		
Market return	7.50 %	Cyclicality	2.00	Hybrid capital	0		
Risk free rate	2.00 %	Transparency	1.10	Minority interest	0		
		Others	1.60	Market val. of investments	0		
				Liquidity	22	No. of shares (m)	4.0
WACC	5.48 %	Beta	1.64	Equity Value	312	Value per share (EUR)	77.91

Sens	itivity va	alue per Sh	are (EUR)													
		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
2.09	6.5 %	36.23	39.17	42.40	45.95	49.87	54.23	59.11	2.09	6.5 %	17.57	27.03	36.49	45.95	55.40	64.86	74.32
1.87	6.0 %	47.62	51.37	55.51	60.12	65.27	71.07	77.64	1.87	6.0 %	28.61	39.11	49.61	60.12	70.62	81.12	91.63
1.75	5.7 %	54.20	58.46	63.19	68.48	74.44	81.20	88.93	1.75	5.7 %	35.12	46.24	57.36	68.48	79.60	90.72	101.84
1.64	5.5 %	61.48	66.35	71.79	77.91	84.85	92.80	101.97	1.64	5.5 %	42.47	54.28	66.09	77.91	89.72	101.54	113.35
1.53	5.2 %	69.60	75.19	81.48	88.61	96.78	106.21	117.22	1.53	5.2 %	50.81	63.41	76.01	88.61	101.22	113.82	126.42
1.41	5.0 %	78.69	85.15	92.49	100.88	110.57	121.89	135.28	1.41	5.0 %	60.37	73.87	87.37	100.88	114.38	127.88	141.39
1.19	4.5 %	100.57	109.44	119.67	131.63	145.78	162.79	183.63	1.19	4.5 %	84.34	100.11	115.87	131.63	147.39	163.16	178.92

^{• ...}



Valuation							
	2018	2019	2020	2021	2022e	2023e	2024e
Price / Book	1.5 x	1.4 x	1.3 x	1.8 x	1.1 x	1.0 x	0.9 x
Book value per share ex intangibles	23.65	26.30	28.29	31.48	34.79	38.54	43.30
EV / Sales	1.2 x	1.2 x	1.3 x	1.3 x	1.1 x	1.1 x	1.0 x
EV / EBITDA	12.9 x	13.0 x	14.0 x	14.5 x	11.5 x	10.8 x	9.5 x
EV / EBIT	14.1 x	14.4 x	15.6 x	16.0 x	12.5 x	11.7 x	10.2 x
EV / EBIT adj.*	13.4 x	14.0 x	14.9 x	14.8 x	12.3 x	11.4 x	10.0 x
P/FCF	n.a.						
P/E	10.2 x	9.4 x	9.6 x	12.5 x	7.8 x	7.0 x	5.8 x
P / E adj.*	10.2 x	9.4 x	9.6 x	12.5 x	7.8 x	7.0 x	5.8 x
Dividend Yield	3.5 %	4.9 %	4.2 %	2.9 %	4.9 %	5.3 %	5.3 %
FCF Potential Yield (on market EV)	5.1 %	5.0 %	4.7 %	4.7 %	5.9 %	6.3 %	7.1 %
*Adjustments made for: -							


Company Specific Items							
	2018	2019	2020	2021	2022e	2023e	2024e
Order intake	278.6	296.5	312.5	446.6	356.0	369.3	383.2
Total output	279.0	273.0	310.3	355.7	374.6	381.9	419.1
Material expenses	217.1	207.8	241.7	272.2	289.9	293.1	322.0
Gross margin adj.	23.8 %	24.5 %	24.1 %	24.7 %	23.2 %	23.9 %	23.7 %
Order book	n.a.						



Consolidated profit & loss							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024
Sales	253.3	263.2	274.0	331.5	364.6	371.9	409.1
Change Sales yoy	-5.0 %	3.9 %	4.1 %	21.0 %	10.0 %	2.0 %	10.0 %
Increase / decrease in inventory	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
Own work capitalised	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
Total output	279.0	273.0	310.3	355.7	374.6	381.9	419.1
Material expenses	217.1	207.8	241.7	272.2	289.9	293.1	322.0
Gross profit	61.9	65.3	68.6	83.5	84.8	88.8	97.1
Gross profit margin	24.5 %	24.8 %	25.0 %	25.2 %	23.2 %	23.9 %	23.7 %
Personnel expenses	23.9	25.0	26.6	29.0	30.2	31.2	32.3
Other operating income	1.6	2.6	2.7	1.6	2.0	2.0	2.0
Other operating expenses	15.9	17.7	19.9	25.4	23.0	22.5	23.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	23.8	25.2	24.8	30.6	33.6	37.1	43.8
Margin	9.4 %	9.6 %	9.0 %	9.2 %	9.2 %	10.0 %	10.7 %
Depreciation of fixed assets	2.0	2.4	2.6	2.7	2.8	2.8	2.8
EBITA	21.8	22.8	22.2	27.9	30.8	34.3	41.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	21.8	22.8	22.2	27.9	30.8	34.3	41.0
Margin	8.6 %	8.7 %	8.1 %	8.4 %	8.4 %	9.2 %	10.0 %
EBIT adj.	22.9	23.5	23.2	30.2	31.5	35.0	41.7
Interest income	0.1	1.7	0.9	0.1	0.2	0.3	0.3
Interest expenses	0.7	0.9	0.7	0.7	1.1	1.3	1.3
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	21.2	23.6	22.5	27.3	29.9	33.3	40.0
Margin	8.4 %	9.0 %	8.2 %	8.2 %	8.2 %	9.0 %	9.8 %
Total taxes	6.6	7.4	7.1	8.5	9.4	10.5	12.6
Net income from continuing operations	14.5	16.2	15.4	18.8	20.5	22.8	27.4
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	14.5	16.2	15.4	18.8	20.5	22.8	27.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	14.5	16.1	15.4	18.8	20.4	22.8	27.4
Margin	5.7 %	6.1 %	5.6 %	5.7 %	5.6 %	6.1 %	6.7 %
Number of shares, average	4.0	4.0	4.0	4.0	4.0	4.0	4.0
EPS	3.62	4.04	3.84	4.69	5.11	5.69	6.84
EPS adj.	3.62	4.04	3.84	4.69	5.11	5.69	6.84
*Adjustments made for:							

Guidance: 2022: Sales EUR 360-380m, EBT EUR 30-33m; 2024: Sales EUR >>400m. EBT EUR >>40m


Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Total Operating Costs / Sales	100.8 %	94.2 %	104.2 %	98.1 %	93.5 %	92.7 %	91.7 %
Operating Leverage	-2.5 x	1.2 x	-0.7 x	1.2 x	1.0 x	5.8 x	2.0 x
EBITDA / Interest expenses	34.7 x	29.0 x	38.1 x	42.0 x	30.5 x	28.5 x	33.7 x
Tax rate (EBT)	31.4 %	31.4 %	31.5 %	31.1 %	31.5 %	31.5 %	31.5 %
Dividend Payout Ratio	35.8 %	45.7 %	40.0 %	36.6 %	38.1 %	36.8 %	30.7 %
Sales per Employee	779,311	817,525	791,887	952,546	1,027,255	1,027,255	1,107,825





Consolidated balance sheet							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Assets							
Goodwill and other intangible assets	3.0	3.3	3.3	3.4	3.7	4.0	4.3
thereof other intangible assets	1.6	1.9	1.9	2.0	2.3	2.6	2.9
thereof Goodwill	1.4	1.4	1.4	1.4	1.4	1.4	1.4
Property, plant and equipment	19.1	19.9	19.5	19.3	19.1	19.2	19.3
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	4.6	4.6	2.2	2.3	2.4	2.5
Fixed assets	22.2	27.9	27.5	25.0	25.2	25.7	26.2
Inventories	220.2	232.2	281.7	311.0	330.0	360.0	390.0
Accounts receivable	77.2	96.6	87.8	86.3	99.9	101.9	112.1
Liquid assets	16.3	16.7	20.1	21.8	21.5	22.5	23.2
Other short-term assets	5.5	6.8	6.3	7.4	6.3	6.4	6.6
Current assets	319.2	352.3	395.9	426.5	457.7	490.8	531.9
Total Assets	341.4	380.2	423.4	451.4	482.9	516.5	558.1
Liabilities and shareholders' equity							
Subscribed capital	4.0	4.0	4.0	4.0	4.0	4.0	4.0
Capital reserve	41.5	41.5	41.6	41.8	41.8	41.8	41.8
Retained earnings	30.9	36.3	43.7	49.9	63.4	78.4	97.4
Other equity components	21.2	26.7	27.2	33.6	33.6	33.9	34.3
Shareholders' equity	97.6	108.5	116.5	129.3	142.9	158.2	177.5
Minority interest	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total equity	97.7	108.6	116.6	129.5	143.0	158.3	177.7
Provisions	25.5	33.4	33.3	30.8	32.8	34.9	37.7
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilities (total)	175.6	192.4	219.2	233.5	247.8	263.7	281.3
Short-term financial liabilities	33.0	36.0	36.9	20.6	23.7	27.3	31.4
Accounts payable	9.5	15.0	16.0	16.3	18.0	18.3	20.2
Other liabilities	33.1	30.7	38.4	41.3	41.3	41.3	41.3
Liabilities	243.7	271.6	306.8	321.9	339.9	358.2	380.4
Total liabilities and shareholders' equity	341.4	380.2	423.4	451.4	482.9	516.5	558.1


Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Efficiency of Capital Employment							
Operating Assets Turnover	0.8 x	0.8 x	0.7 x	0.8 x	0.8 x	0.8 x	0.8 x
Capital Employed Turnover	1.0 x	0.9 x	0.9 x	1.0 x	1.0 x	0.9 x	0.9 x
ROA	65.1 %	57.9 %	55.9 %	75.2 %	81.1 %	88.7 %	104.4 %
Return on Capital							
ROCE (NOPAT)	6.0 %	5.8 %	5.1 %	5.9 %	5.9 %	6.1 %	6.7 %
ROE	15.6 %	15.7 %	13.7 %	15.3 %	15.0 %	15.1 %	16.3 %
Adj. ROE	15.6 %	15.7 %	13.7 %	15.3 %	15.0 %	15.1 %	16.3 %
Balance sheet quality							
Net Debt	159.3	175.7	199.1	211.7	226.3	241.2	258.1
Net Financial Debt	159.3	175.7	199.1	211.7	226.3	241.2	258.1
Net Gearing	163.0 %	161.8 %	170.8 %	163.5 %	158.2 %	152.4 %	145.3 %
Net Fin. Debt / EBITDA	670.1 %	698.2 %	804.1 %	690.9 %	674.4 %	650.1 %	589.2 %
Book Value / Share	24.4	27.1	29.1	32.3	35.7	39.5	44.4
Book value per share ex intangibles	23.7	26.3	28.3	31.5	34.8	38.5	43.3





Consolidated cash flow statement							
In EUR m	2018	2019	2020	2021	2022e	2023e	2024e
Net income	14.5	16.2	15.4	18.8	20.5	22.8	27.4
Depreciation of fixed assets	2.0	2.4	2.6	2.7	2.8	2.7	2.7
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	0.1	-0.1	0.1	0.3	0.0	0.0	0.0
Other non-cash income and expenses	-1.6	-0.3	2.2	2.5	1.0	1.0	1.0
Cash Flow before NWC change	14.9	18.1	20.4	24.4	24.3	26.5	31.1
Increase / decrease in inventory	-16.9	-8.6	-45.5	-25.3	-19.0	-30.0	-30.0
Increase / decrease in accounts receivable	-1.3	-25.0	8.3	2.4	-13.6	-2.0	-10.2
Increase / decrease in accounts payable	-1.0	4.0	7.7	1.9	1.7	0.3	1.9
Increase / decrease in other working capital positions	8.3	8.0	-0.2	-2.8	5.8	6.5	6.5
Increase / decrease in working capital (total)	-10.9	-21.6	-29.7	-23.8	-25.1	-25.2	-31.8
Net cash provided by operating activities [1]	4.1	-3.5	-9.3	0.5	-0.9	1.3	-0.7
Investments in intangible assets	-0.7	-0.6	-0.5	-0.7	-0.6	-0.6	-0.6
Investments in property, plant and equipment	-4.4	-3.0	-2.3	-2.0	-2.6	-2.8	- 2.8
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	-0.1	-0.1	-0.2	-0.2	0.0	0.0	0.0
Income from asset disposals	0.5	0.1	0.6	0.2	0.5	0.5	0.5
Net cash provided by investing activities [2]	-4.4	-2.0	-1.9	-2.0	-2.7	-2.9	-2.9
Change in financial liabilities	9.7	15.8	26.9	14.4	14.3	15.9	17.6
Dividends paid	-5.6	-5.2	-7.4	-6.2	- 6.9	-7.8	-8.4
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-4.1	-4.7	-4.9	-5.1	-4.1	-5.5	-4.9
Net cash provided by financing activities [3]	0.1	5.9	14.6	3.2	3.3	2.6	4.3
Change in liquid funds [1]+[2]+[3]	-0.3	0.4	3.4	1.7	-0.3	1.0	0.7
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	16.3	16.7	20.1	21.8	21.5	22.5	23.2

Financial Ratios							
	2018	2019	2020	2021	2022e	2023e	2024e
Cash Flow							
FCF	-1.0	-5.8	-12.0	-1.8	-4.1	-2.1	-4.1
Free Cash Flow / Sales	-0.4 %	-2.2 %	-4.4 %	-0.6 %	-1.1 %	-0.6 %	-1.0 %
Free Cash Flow Potential	15.7	16.4	16.3	20.8	22.8	25.2	29.8
Free Cash Flow / Net Profit	-6.8 %	-35.8 %	<i>-</i> 77.8 %	-9.8 %	-20.0 %	-9.2 %	-15.0 %
Interest Received / Avg. Cash	0.3 %	10.2 %	5.1 %	0.5 %	0.9 %	1.4 %	1.3 %
Interest Paid / Avg. Debt	0.4 %	0.5 %	0.3 %	0.3 %	0.5 %	0.5 %	0.5 %
Management of Funds							
Investment ratio	2.0 %	1.4 %	1.1 %	0.8 %	0.9 %	0.9 %	0.8 %
Maint. Capex / Sales	0.6 %	0.5 %	0.5 %	0.4 %	0.4 %	0.4 %	0.3 %
Capex / Dep	253.1 %	150.0 %	111.4 %	97.7 %	114.3 %	121.4 %	121.4 %
Avg. Working Capital / Sales	109.8 %	114.3 %	121.8 %	110.8 %	108.7 %	115.0 %	113.1 %
Trade Debtors / Trade Creditors	812.2 %	642.2 %	549.7 %	527.9 %	555.0 %	556.8 %	555.0 %
Inventory Turnover	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Receivables collection period (days)	111	134	117	95	100	100	100
Payables payment period (days)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Cash conversion cycle (Days)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.





LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

8



SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- **-6c-** The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)		
HELMA Eigenheimbau	3, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A0EQ578.htm		



INVESTMENT RECOMMENDATION

Rating suspended

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.			
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.			
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.			
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.			

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING					
Rating	Number of stocks	% of Universe			
Buy	172	80			
Hold	36	17			
Sell	3	1			

Total 214 100


3

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	52	87
Hold	5	8
Sell	1	2
Rating suspended	2	3
Total	60	100

PRICE AND RATING HISTORY HELMA EIGENHEIMBAU AS OF 28.06.2022



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Philipp Kaiser Real Estate	+49 40 309537-260 pkaiser@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com
Stefan Augustin	+49 40 309537-168	Eggert Kuls	+49 40 309537-256
Cap. Goods, Engineering	saugustin@warburg-research.com	Engineering	ekuls@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Jonas Blum Telco, Media, Construction	+49 40 309537-240 jblum@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Christian Cohrs	+49 40 309537-175	Oliver Schwarz	+49 40 309537-250
Industrials & Transportation	ccohrs@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Simon Stippig Real Estate	+49 40 309537-265 sstippig@warburg-research.com
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Cansu Tatar Cap. Goods, Engineering	+49 40 309537-248 ctatar@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Marius Fuhrberg	+49 40 309537-185	Robert-Jan van der Horst	+49 40 309537-290
Financial Services	mfuhrberg@warburg-research.com +49 40 309537-230	Technology	rvanderhorst@warburg-research.com +49 40 309537-140
Mustafa Hidir Automobiles, Car Suppliers	+49 40 309537-230 mhidir@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Thor Höfs	+49 40 309537-255		
Software, IT	thoefs@warburg-research.com		
INSTITUTIONAL EQUI	TY SALES		
Marc Niemann	+49 40 3282-2660	Maximilian Martin	+49 69 5050-7413
Head of Equity Sales, Germany	mniemann@mmwarburg.com	Austria, Poland	mmartin@mmwarburg.com
Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400 kschilling@mmwarburg.com	Christopher Seedorf Switzerland	+49 40 3282-2695 cseedorf@mmwarburg.com
Tim Beckmann	+49 40 3282-2665		
United Kingdom	tbeckmann@mmwarburg.com		
Lea Bogdanova United Kingdom, Ireland	+49 69 5050-7411 lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415		
Scandinavia, Austria	jbuchmueller@mmwarburg.com		
Alexander Eschweiler	+49 40 3282-2669	Sophie Hauer	+49 69 5050-7417
Germany, Luxembourg	aeschweiler@mmwarburg.com	Roadshow/Marketing	shauer@mmwarburg.com
Matthias Fritsch United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
-	a.barg.com		jinomam@immarsarg.com
SALES TRADING			
Oliver Merckel Head of Sales Trading	+49 40 3282-2634 omerckel@mmwarburg.com	Marcel Magiera Sales Trading	+49 40 3282-2662 mmagiera@mmwarburg.com
Elyaz Dust	+49 40 3282-2702	Bastian Quast	+49 40 3282-2701
Sales Trading	edust@mmwarburg.com	Sales Trading	bquast@mmwarburg.com
Michael Ilgenstein	+49 40 3282-2700	Jörg Treptow	+49 40 3282-2658
Sales Trading MACRO RESEARCH	milgenstein@mmwarburg.com	Sales Trading	jtreptow@mmwarburg.com
Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
Our research can be fo	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	Refinitiv	www.refinitiv.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
_	ct·		
For access please conta	Ot.		
For access please conta Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703